LATEST NEWS
Chemical Society Reviews Journal Explores How OncoTEX’s Gold-Based Compounds Can Activate the Immune System to Fight Cancer
OncoTEX Inc., an oncology company developing first in class cancer therapeutics that are well-tolerated, MRI-detectable, and target drug-sensitive and drug-resistant solid tumors, today announced its submission in the peer-reviewed Chemical Society Reviews, exploring the novel gold compound platform technology AuraTEX, and how the human body’s immune system can destroy cancer cells.
Gold Technology for Immune Response Cancer Therapy Licensed to OncoTEX
OncoTEX Inc. (OncoTEX), a US oncology company and member of The iQ Group Global portfolio, is pleased to announce it has received licensing for a gold compound platform technology that induces the body’s immune system to destroy cancer cells.
OncoTEX Inc. appoints Chief Executive Officer
OncoTEX Inc. (OncoTEX), a US oncology company and member of The iQ Group Global Ltd portfolio (NSX.IQG), is pleased to announce it has appointed Dr. Jonathan F. Arambula as Chief Executive Officer.
Production Underway on a New Weapon to Fight Ovarian Cancer
A significant manufacturing agreement between OncoTEX Inc. (OncoTEX) and Sterling Pharma Solutions will see the production of novel platinum-resistant cancer-fighting drug, OxaliTEX, scaled up for preclinical and clinical testing.
Novel Cancer-Fighting Drug Candidate OxaliTEX Receives Australian Patent Approval
A pre-clinical platinum-resistant cancer-fighting drug candidate that localises to tumour cells is granted a patent in Australia.
Cancer Drug Found to have ‘Better Staying Power, Reduced Toxicity’ in Preclinical Trial – University of Texas at Austin
UNIVERSITY OF TEXAS AT AUSTIN – A drug candidate has been found in preclinical trials to stop tumor growth entirely, deliver more cancer-busting power than many commonly used chemotherapy drugs and do so with fewer toxic side effects and more ability to overcome resistance.
World Renowned Professor of Chemistry, Professor Jonathan Sessler Appointed to the OncoTEX Inc. Board
One of the world’s most renowned Chemists and co-founder of the biopharmaceutical company, Pharmacyclics, Professor Jonathan L. Sessler has been appointed as a Non-Executive Director to the board of OncoTEX Inc., it was announced today.
The iQ Group Global Welcomes Dr. Jonathan Arambula as Vice President of Research, OncoTEX Inc.
The iQ Group Global, an enterprise dedicated to developing early stage bioscience assets, announced that Dr. Jonathan Arambula will join The iQ Group Global as the Vice President of Research, OncoTEX Inc.
FEATURED IN
Novel and Less Toxic Anticancer Drug Candidate Developed
Drug candidate stops tumour growth with little toxicity in mice
Drug Candidate Could Deliver More Cancer-busting Power Than Chemo
Trial of cancer drug OxaliTex promises lower toxicity and more robust action
Cancer Drug with Better Staying Power and Reduced Toxicity Shows Promise in Preclinical Trials
Cancer drug with better staying power, reduced toxicity promising in preclinical trial
At a crossroads': Calls for biotech investment rethink
The iQ Group Global Acquires New Anticancer Drug Platform from the University of Texas
The iQ Group Global Acquires New Anticancer Drug Platform from the University of Texas
The iQ Group Global Acquires New Anticancer Drug Platform from the University of Texas
Request Further Information
Member of The iQ Group Global
OncoTEX Inc. is a proud member of The iQ Group Global, a consortium of companies who work together to find, fund and develop bioscience discoveries into life-changing medical innovations – and take them to the people who need them most.
